Medical Products

ReliDoce (Docetaxel) is an antineoplastic agent belonging to the taxoid family. Docetaxel acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions. Docetaxel binds to free tubulin and promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly.

The approved indications include treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy, adjuvant treatment of patients with operable node-positive breast cancer (used in combination with doxorubicin and cyclophosphamide), treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy, treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition (used in combination with cisplatin), treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer (used in combination with prednisone), treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease (used in combination with cisplatin and fluorouracil) and induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) (used in combination with cisplatin and fluorouracil).